957783-10-7

Usage

Uses

Used in Organic Synthesis:
(4-Hydroxymethyl-phenyl)-carbamic acid benzyl ester is used as a reagent in organic synthesis for its ability to facilitate various chemical reactions and contribute to the formation of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (4-Hydroxymethyl-phenyl)-carbamic acid benzyl ester serves as a valuable compound for research purposes, aiding in the development and understanding of new drug candidates and their mechanisms of action.
Used as an Insecticide in Agriculture:
(4-Hydroxymethyl-phenyl)-carbamic acid benzyl ester, under the trade name Bendiocarb, is employed as an insecticide to control pests in agricultural settings. Its effectiveness in managing insect populations helps protect crops and maintain agricultural productivity.
Used in Public Health:
Beyond agriculture, Bendiocarb is also utilized in public health initiatives to control insect-borne diseases by reducing the populations of disease-carrying insects, such as mosquitoes and flies.
Used as a Pharmaceutical Intermediate:
(4-Hydroxymethyl-phenyl)-carbamic acid benzyl ester has demonstrated potential as a pharmaceutical intermediate, playing a crucial role in the synthesis of new drugs and contributing to advancements in the pharmaceutical industry.

Upstream product

• 623-04-1 4-aminobenzenemethanol 
• 501-53-1 benzyl chloroformate 
• 555-16-8 4-nitrobenzaldehdye 
• 71150-68-0 benzyl N-(4-formylphenyl)carbamate 

Downstream Products

• 1414968-21-0 Methanesulfonic acid 4-benzyloxycarbonylamino-benzyl ester 
• 1414968-22-1 [1-(4-Benzyloxycarbonylamino-benzyl)-piperidin-4-yl]-carbamic acid tert-butyl ester 
• 1392490-92-4 [4-(4-Acryloylamino-piperidin-1-ylmethyl)-phenyl]carbamic acid benzyl ester 
• 840501-01-1 N-{(S)-3-[4-((E)-2-Benzotriazol-2-yl-2-cyano-vinyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide 
• 840501-00-0 N-{3-[4-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-2-oxo-oxazolidin-5-ylmethyl}-acetamide 
• 840500-99-4 5-azidomethyl-3-[4-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-oxazolidin-2-one 
• 840500-98-3 3-[4-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-5-hydroxymethyl-oxazolidin-2-one 
• 128821-65-8 (S)-N-<<3-<4-(hydroxymethyl)phenyl>-2-oxo-5-oxazolidinyl>methyl>acetamide 
• 114992-47-1 (S)-N-<<3-(4-formylphenyl)-2-oxo-5-oxazolidinyl>methyl>acetamide 

Relevant academic research and scientific papers

Chemoselective continuous-flow hydrogenation of aldehydes catalyzed by platinum nanoparticles dispersed in an amphiphilic resin

A chemoselective continuous-flow hydrogenation of aldehydes catalyzed by a dispersion of platinum nanoparticles in an amphiphilic polymer (ARP-Pt) has been developed. Aromatic and aliphatic aldehydes bearing various reducible functional groups, such as keto, ester, or amide groups, readily underwent flow hydrogenation in aqueous solutions within 22 s in a continuous-flow system containing ARP-Pt to give the corresponding primary benzylic or aliphatic alcohols in ≤99% yield with excellent chemoselectivity. Moreover, the long-term continuous-flow hydrogenation of benzaldehyde for 8 days was realized, and the total turnover number of the catalyst reached 997. The flow hydrogenation system provides an efficient and practical method for the chemoselective hydrogenation of aldehydes bearing reducible functional groups.

TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.

Effects of positional and geometrical isomerism on the biological activity of some novel oxazolidinones

Some novel oxazolidinone derivatives have been synthesized and tested for antibacterial activity. Compound 13 was found to be active against Gram-positive pathogens whereas compound 14 was less active. Either less active or inactive molecules were obtained, when benzotriazole was replaced with benzimidazole, benzthiazole, or benzoxazole. However, thioacetamide analogue of 13 produced a potent molecule similar to linezolid in vitro. Some novel oxazolidinone derivatives with benzotriazole as pendant have been synthesized and tested for antibacterial activity. Linearly attached benzotriazole derivative showed more potency compared to angular one in vitro. Out of E/Z-isomers of angularly attached derivatives E-isomer was found to be more potent than Z-isomer. Either less active or inactive molecules were obtained, when benzotriazole was replaced with benzimidazole, benzthiazole, or benzoxazole. Finally, thioacetamide analogue of linear compound gave a lead having activity similar to linezolid in vitro.